Complications of peripheral angioplasty access

Original title: Access Site Complications After Peripheral Vascular Interventions. Incidence, Predictors, and Outcomes. Reference: Daniel Ortiz et al. Circ Cardiovasc Interv. 2014 Nov 11. Epub ahead of print.

 

Hematomas and pseudoaneurysms are the most common complications of peripheral angioplasty, though its incidence and risk factors are unclear. A retrospective analysis was performed in 22226 patients receiving peripheral angioplasty between 2007 and 2013 at several centers. The primary end points included the incidence and complication predictors related to vascular access, post procedure length of stay and mortality at 30 days and one year. Access complications occurred in 936 procedures (3.5%). Of these, 74.4% were minor, 9.7% were moderate requiring transfusion, 5.4% were moderate requiring thrombin injection and 10.5% were severe complications requiring surgery.

Predictors of complications related to access were age (>75 years), female gender, access different to femoral, introducer >6 Fr, use of thrombolytics, arterial dissection, fluoroscopy time     >30 minutes, urgent indication and the absence of percutaneous closure devices procedure. In patients who had complications access, hospital stay was significantly higher (1.2 ± 1.6 versus 1.9 ± 1.9 days; p = 0.002) and in which the complication was severe, an increased mortality was observed at 30 days (6.1% versus 1.4%; p <0.001). In those which complication was moderate but requiring transfusion, mortality was higher per year (12.1% versus 5.7%, p <0.001).

Conclusion

Several factors independently predict the risk of complications of vascular access in patients receiving peripheral angioplasty. The appropriate use of anti-thrombotic and vascular closure devices could improve results.

Editorial comment

This issue, which has been widely analyzed in coronary angioplasty, did not have much data for peripheral angioplasty. Two of the most useful resources in coronary angioplasty as radial access and use of bivalirudin, have technical limitations or insufficient evidence in the peripheral angioplasty. The radial access may be useful in selected cases of renal angioplasty, iliac primitive or carotid, but not much further. Bivalirudin has some evidence in carotid angioplasty but not in other territories.

SOLACI

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...